Insights / Whitepapers
Tokenized data: the power to deliver robust patient insights in a complex real world
Written by Shea O’Connell, Viktor Chirikov, Xiaocong Li, Hannah Matthews and Michael Chance on Wednesday, November 5, 2025
HTA bodies routinely demand real-world evidence (RWE) to support reimbursement decisions for new therapies under consideration. Yet as patient treatment journeys become more complex, encompassing primary, secondary, and multidisciplinary care delivered by different providers with different systems, it becomes more challenging to model those patient treatment journeys for evidence generation.
Capturing the rich evidence in complex patient journeys is possible, however, with tokenized real-world data (RWD). In this whitepaper, OPEN Health’s RWE experts explain what tokenized real-world data (RWD) is and show via two case studies (one US, one UK) how it can be the key to a robust integrated evidence generation plan that satisfies HTA requirements.
We have reserved a copy of this whitepaper for you.
OPEN Health authors – RWE and Market Access Experts:

At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.
By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across Medical Affairs and market access unlocks faster, smarter routes to market.
OPEN Health. The right combination to unlock possibilities.
For information about OPEN Health’s services and how we could support you, please get in touch.
We are excited to share our latest thinking with you. Please fill out the form to download the whitepaper.
"*" indicates required fields
Something went wrong. Please try again.
Tokenized data: the power to deliver robust patient insights in a complex real world
Whitepapers•HEOR & market access, Market access strategy, Real-world evidence & data analytics
Bridging the Gap: Evidence Challenges for Advanced and Orphan Therapies in the EU HTA Landscape
Whitepapers•Pricing & market access, HEOR & market access, Market access strategy
Smarter SLRs or Risky Shortcuts? Perspectives From Global HTA Stakeholders
Whitepapers•HEOR & market access, Market access strategy